Background Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …

Aims Patients with chronic heart failure (CHF) show impaired health-related quality of life
(HRQoL), an important target for therapeutic intervention. Impaired iron homeostasis may be …

Aims Patients with heart failure (HF) and iron deficiency experience poor health-related
quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose …

Aims Iron deficiency (ID) is a common co‐morbidity in patients with heart failure (HF) and
has been suggested to be associated with poor prognosis. Recently completed double …

Aims Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron
substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in …

Aim Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of
life in iron‐deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial …

Aim The aim of this study was to evaluate the benefits and safety of long-term iv iron therapy
in iron-deficient patients with heart failure (HF). Methods and results CONFIRM-HF was a …

Introduction Iron administration especially intravenous iron therapy is associated with
improvements in exercise capacity and quality of life in patients with chronic heart failure …

Aims Iron deficiency is common in patients with heart failure (HF). In AFFIRM‐AHF, ferric
carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved …

Aims Iron deficiency (ID) is a common co‐morbidity in heart failure (HF), associated with
impaired functional capacity, poor quality of life and increased morbidity and mortality …